Cencora, Inc. (COR)

On our desk, the recent 19% pullback from earlier highs looks like a textbook window for institutional accumulation, especially given that major players like Morgan Stanley and T. Rowe Price are ramping up positions. With the company raising its fiscal 2026 adjusted EPS guidance to a range of $17.75–$17.95 and backing it with a $2 billion share buyback authorization, the valuation thesis is holding firm. Trading at a forward P/E of roughly 15.7x to 16x alongside a tailored fair P/E framework sitting near 27.1x, the multiple feels undemanding for a high-performing member of the Big Three drug wholesalers.

From a clinical logistics perspective, our focus is entirely on how well Cencora executes its pivot into a specialty medicines infrastructure provider. The numbers from Q3 show that gross profit rose significantly due to specialty platforms like OneOncology and Retina Consultants of America. However, when we evaluate their ability to manage complex Part B biosimilars and cell therapies, supply chain resilience remains paramount. The infrastructure investments are clearly deepening client retention and driving margin expansion up to 4.31%, but operational execution in high-touch specialty distribution must remain flawless to justify long-term EPS growth targets of 10–14%.

Watching the 50-day moving average recover toward $280 and shares closing near $311 highlights positive short-term momentum, but we cannot ignore the underlying risk factors. High customer concentration, ongoing regulatory scrutiny, and the inherent liabilities of debt leverage from aggressive MandA activity introduce hidden vulnerabilities. Furthermore, as the market digests list price changes and brand-to-generic conversions, any unexpected shifts in GLP-1 drug volume trends could introduce sudden earnings volatility. Investors need to watch whether the upcoming Q4 updates maintain this tight guidance range or reveal strain from integration costs.